HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women

HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women

Abstract Background The sensitivity of estrogen receptor-positive breast cancers to tamoxifen treatment varies considerably, and the molecular mechanisms affecting the response rates are manifold. The human epidermal growth factor receptor-related receptor HER2 is known to trigger intracellular sign...

Full description

Bibliographic Details
Main Authors: Anja Kathrin Wege, Dominik Chittka, Stefan Buchholz, Monika Klinkhammer-Schalke, Simone Diermeier-Daucher, Florian Zeman, Olaf Ortmann, Gero Brockhoff
Format: Article
Language:English
Published: BMC 2018-11-01
Series:Breast Cancer Research
Subjects:
HER4 receptor
Estrogen receptor positive breast cancer
Tamoxifen treatment
Online Access:http://link.springer.com/article/10.1186/s13058-018-1072-1

Internet

http://link.springer.com/article/10.1186/s13058-018-1072-1

Similar Items